204 The cardiac hepcidin/ferroportin axis is essntial for cardiac iron homeostasis and function. (5th June 2017)
- Record Type:
- Journal Article
- Title:
- 204 The cardiac hepcidin/ferroportin axis is essntial for cardiac iron homeostasis and function. (5th June 2017)
- Main Title:
- 204 The cardiac hepcidin/ferroportin axis is essntial for cardiac iron homeostasis and function
- Authors:
- Lakhal-Littleton, Samira
Wolna, Magda
Chung, Yu-Jin
Christian, Helen
Heather, Lisa
Brescia, Marcella
Ball, Vicky
Diaz, Rebeca
Santos, Ana
Biggs, Daniel
Clarke, Kieran
Davies, Benjamin
Robbins, Peter - Abstract:
- Abstract : Background: Iron deficiency and chronic heart failure are two of the most common disorders worldwide. Recent evidence has demonstrated that they are linked. Moreover, clinical trials have demonstrated the benefits of intravenous iron supplementation in chronic heart failure. However, cardiac iron homeostasis remains unexplored. Recently, our laboratory demonstrated that cardiac-specific deletion of the ?iron-?exporting protein ferroportin causes fatal cardiac iron overload1. Ferroportin is known to be downregulated by the liver-derived hormone hepcidin. But hepcidin is also found in cardiomyocytes where its function remains unknown. Methods and results: To explore the function of cardiomyocyte hepcidin, we generated mice with a cardiomyocyte-specific deletion of hepcidin or with a cardiomyocyte-specific knock-in of a hepcidin-resistant ferroportin mutant. While both models maintain normal systemic iron homeostasis, they nevertheless develop cardiomyocyte metabolic dysfunction followed by fatal contractile impairment as a consequence of cardiomyocyte iron deficiency. Intravenous iron supplementation prevents both the development of metabolic dysfunction and contractile impairment. 2 Conclusions: We conclude that regulation of iron export from cardiomyocytes by the cardiac hepcidin/ferroportin axis is essential to cardiomyocyte iron homeostasis and that its disruption leads to fatal cardiac dysfunction, even against a background of intact systemic iron homeostasis.Abstract : Background: Iron deficiency and chronic heart failure are two of the most common disorders worldwide. Recent evidence has demonstrated that they are linked. Moreover, clinical trials have demonstrated the benefits of intravenous iron supplementation in chronic heart failure. However, cardiac iron homeostasis remains unexplored. Recently, our laboratory demonstrated that cardiac-specific deletion of the ?iron-?exporting protein ferroportin causes fatal cardiac iron overload1. Ferroportin is known to be downregulated by the liver-derived hormone hepcidin. But hepcidin is also found in cardiomyocytes where its function remains unknown. Methods and results: To explore the function of cardiomyocyte hepcidin, we generated mice with a cardiomyocyte-specific deletion of hepcidin or with a cardiomyocyte-specific knock-in of a hepcidin-resistant ferroportin mutant. While both models maintain normal systemic iron homeostasis, they nevertheless develop cardiomyocyte metabolic dysfunction followed by fatal contractile impairment as a consequence of cardiomyocyte iron deficiency. Intravenous iron supplementation prevents both the development of metabolic dysfunction and contractile impairment. 2 Conclusions: We conclude that regulation of iron export from cardiomyocytes by the cardiac hepcidin/ferroportin axis is essential to cardiomyocyte iron homeostasis and that its disruption leads to fatal cardiac dysfunction, even against a background of intact systemic iron homeostasis. These findings raise the possibility that hepcidin agonists/antagonists developed for disorders of systemic iron homeostasis could also modulate cardiac function. References: 1. Lakhal-Littletonet al. An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. Elife. 2016Nov 29;5. pii: e19804. doi: 10.7554/eLife.19804. 2. Lakhal-Littletonet al. Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. PNAS, 2015;112, 3164–3169. … (more)
- Is Part Of:
- Heart. Volume 103(2017)Supplement 5
- Journal:
- Heart
- Issue:
- Volume 103(2017)Supplement 5
- Issue Display:
- Volume 103, Issue 5 (2017)
- Year:
- 2017
- Volume:
- 103
- Issue:
- 5
- Issue Sort Value:
- 2017-0103-0005-0000
- Page Start:
- A137
- Page End:
- A137
- Publication Date:
- 2017-06-05
- Subjects:
- HEPCIDIN -- FERROPORTIN -- IRON
Heart -- Diseases -- Treatment -- Periodicals
Cardiology -- Periodicals
616.12 - Journal URLs:
- http://www.bmj.com/archive ↗
http://heart.bmj.com ↗
http://www.heartjnl.com ↗ - DOI:
- 10.1136/heartjnl-2017-311726.202 ↗
- Languages:
- English
- ISSNs:
- 1355-6037
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19675.xml